Mannkind CORP: management transactions · United States · SEC (Form 4)

About Mannkind CORP

MannKind Corp. (ticker MNKD) is a U.S.-listed biopharmaceutical company traded on the Nasdaq in the United States. Founded in 1991 and currently headquartered in Danbury, Connecticut, the company focuses on developing and commercializing innovative therapeutic products and delivery devices aimed at serious chronic diseases. Its core strategy centers on cardiometabolic and orphan lung conditions, with manufacturing and technical operations anchored in Connecticut. ([investors.mannkindcorp.com](https://investors.mannkindcorp.com/investor-relations?utm_source=openai)) The company’s best-known asset is Afrezza®, an ultra rapid-acting inhaled human insulin used to improve glycemic control in adults with diabetes. MannKind also owns the Technosphere® platform, a proprietary inhalation technology that underpins several products and collaborations. That platform has been used in Tyvaso DPI®, a product commercialized by United Therapeutics for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. This gives MannKind a mix of direct product sales and royalty streams, which makes the business model more diversified than a single-product biotech story. ([mannkindcorp.com](https://mannkindcorp.com/about/?utm_source=openai)) In late 2025 and into 2026, MannKind’s commercial footprint expanded further with the addition of FUROSCIX, a marketed furosemide therapy for fluid overload related to heart failure or kidney disease, and with V-Go®, an insulin delivery device. Management has also highlighted near-term regulatory catalysts, including an Afrezza pediatric filing under FDA review, as well as pipeline programs such as MNKD-201 (nintedanib DPI) and other inhalation-based assets. In May 2026, the company announced a ralinepag DPI program with United Therapeutics, reinforcing the importance of strategic partnerships in MannKind’s growth profile. ([investors.mannkindcorp.com](https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-acquire-scpharmaceuticals-accelerating-revenue-growth?utm_source=openai)) From a competitive standpoint, MannKind is a specialized niche player rather than a large-cap pharmaceutical heavyweight. Its edge lies in inhalation science, differentiated drug-device combinations, and the ability to monetize partnered assets in areas where convenience, adherence, and patient experience matter. For investors, MNKD is best viewed as a commercial-stage biopharma with multiple operating levers, but still exposed to FDA timing risk, execution risk, and some revenue concentration. The recent business updates suggest a company trying to broaden its base of commercial assets while preserving optionality through pipeline development and external collaborations. ([investors.mannkindcorp.com](https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-provides-business-updates-and-2026-growth-drivers?utm_source=openai))